- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Voclosporin Maintains Proteinuria Reduction & eGFR in Lupus Nephritis
Voclosporin, a novel calcineurin inhibitor (CNI), has been tested successfully in two pivotal trials in adult patients with lupus nephritis. A recent interim analysis suggests that voclosporin sustains proteinuria reduction and eGFR in patients with lupus nephritis. The findings of the interim analysis were presented at the EULAR 2021 Virtual Congress.
The US FDA has recently approved voclosporin (LUPKYNIS), based on phase 2 and 3 data showing superiority compared to standard of care treatment in complete renal response. However, "The long-term safety and efficacy data of voclosporin has not yet been evaluated beyond 1 year," said Amit Saxena, MD in an interview. Therefore, Dr Amit and his team conducted a controlled extension study, AURORA 2. They recently reported the first interim analysis of the ongoing AURORA 2 study.
In this two years, blinded controlled extension study, the researchers included patients who completed the AURORA 1study. They enrolled 116 patients in the voclosporin arm and 100 patients in the control arm enrolled in the extension study, of which 73 patients in the voclosporin arm and 51 patients in the control arm had received two years of treatment. The patients received either voclosporin (23.7 mg BID) or placebo, in combination with MMF (1 g BID) and low-dose oral steroids according to the randomization schedule. The researchers evaluated the urine protein creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR) in patients with up to two years of total treatment: one year from AURORA 1 and up to one year in AURORA 2.
Key findings of the study were:
- At the pre-treatment baseline (AURORA 1), the researchers noted that the mean UPCR was 3.94 mg/mg in the voclosporin arm and 3.87 mg/mg in the control arm.
- After 2 years, they found that the least-squares mean changes in urine protein creatinine ratio were –3.1mg per mg for those treated with voclosporin and –2.1mg per mg for the placebo group.
- At baseline, they noted that the mean eGFR was 79.6 mL/min for the voclosporin arm and 78.9 mL/min for the control arm.
- After 2 years, they found that the mean eGFR was 79.0 mL/min for the voclosporin arm (n=73) and 82.9 mL/min for the control arm (n=51).
- They observed a small early decrease in mean eGFR in the first four weeks of treatment (in AURORA 1), after which eGFR remained stable throughout year one and year two.
- Also, they reported no new unexpected adverse events in patients who continued with voclosporin treatment compared to control-treated patients for more than one year.
The authors concluded, "Patients in the voclosporin treatment arm maintained meaningful reductions in proteinuria with no change in mean eGFR at two years of treatment. Additional AURORA 2 efficacy and safety data will be provided at the conclusion of the study".
Josepha James (Msc Cinical Research) joined Medical Dialogues as a writer in Medical News Section in 2020 . She covers news in several medical specialties from both national and international journals and associations. She has completed Bachelors in Physician Assistant and then pursued Masters in Clinical Research. She can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751